세계의 성장호르몬 결핍증 시장 규모 조사 : 치료 유형별, 적응증별, 투여 경로별, 유통 채널별, 지역별 예측(2022-2032년)

Global Growth Hormone Deficiency Market is valued approximately at USD 4.38 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.49% over the forecast period 2024-2032. Growth Hormone Deficiency (GHD) is a medical condition where the body does not produce enough growth hormone, a critical substance responsible for growth and development in children and maintaining tissue and organ health in adults. In children, GHD can result in significantly shorter stature compared to peers, delayed puberty, and increased fat around the face and stomach. In adults, symptoms might include reduced bone density, decreased muscle mass, fatigue, and a higher risk of cardiovascular diseases. Diagnosis often involves blood tests to measure hormone levels, stimulation tests, and imaging studies of the brain. Treatment typically includes growth hormone replacement therapy, which involves regular injections of synthetic growth hormone, helping to normalize growth and metabolic functions. Early diagnosis and consistent treatment are crucial for improving outcomes and quality of life for individuals with GHD.

The Global Growth Hormone Deficiency Market is driven by rising incidence of growth hormone deficiencies worldwide is a primary catalyst for market growth. Additionally, the increasing geriatric population, who are more prone to hormonal imbalances, further propels the demand for growth hormone treatments. Furthermore, growing awareness about hormonal deficiencies is anticipated to bolster market expansion. Growth hormone treatments play a critical role in enabling early diagnosis and effective management of various conditions associated with growth hormone deficiency. However, the market faces challenges, such as the shortage of skilled professionals required to administer and monitor growth hormone therapies. Additionally, the complexity of treatment regimens and potential side effects may hinder market growth.

The key regions considered for the Global Growth Hormone Deficiency Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America dominated the growth hormone therapy landscape, a trend expected to continue throughout the forecast period. This regional dominance is attributed to favorable reimbursement policies in the U.S. and a well-established healthcare infrastructure. Furthermore, Asia-Pacific region is anticipated to witness substantial growth, driven by increasing healthcare investments and rising awareness about growth hormone deficiencies.

Major market players included in this report are:

• Novo Nordisk A/S
• Pfizer Inc.
• Merck KGaA
• Eli Lilly and Company
• Novartis AG
• F. Hoffmann-La Roche AG
• Ipsen Pharma
• Ferring Pharmaceuticals
• Anhui Anke Biotechnology (Group) Co., Ltd.
• Zhongshan Sinobioway Hygene Biomedicine Co., Ltd.

The detailed segments and sub-segment of the market are explained below:

By Treatment Type:

• Therapeutic Treatment
• Recombinant Human Growth Hormone
• Human Pituitary Gland Extracts
• Surgery

By Disease Indication:

• Pediatric Growth Hormone Deficiency
• Idiopathic Short Stature
• Small for Gestational Age
• Turner Syndrome
• Adult Growth Hormone Deficiency
• Others (Prader-Willi Syndrome, etc.)

By Route of Administration:

• Subcutaneous
• Intramuscular
• Intravenous

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market

Table of Contents

Chapter 1. Global Growth Hormone Deficiency Market Executive Summary

• 1.1. Global Growth Hormone Deficiency Market Size & Forecast (2022- 2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Treatment Type
  • 1.3.2. By Disease Indication
  • 1.3.3. By Route of Administration
  • 1.3.4. By Distribution Channel
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Growth Hormone Deficiency Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Growth Hormone Deficiency Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Rise in Incidence of Growth Hormone Deficiencies
  • 3.1.2. Increase in Geriatric Population
• 3.2. Market Challenges
  • 3.2.1. Lack of Skilled Professionals
  • 3.2.2. Complexity of Treatment Regimens
• 3.3. Market Opportunities
  • 3.3.1. Growing Awareness about Hormonal Deficiencies
  • 3.3.2. Advancements in Treatment Methodologies
  • 3.3.3. Increasing Healthcare Investments in Emerging Markets

Chapter 4. Global Growth Hormone Deficiency Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Growth Hormone Deficiency Market Size & Forecasts by Treatment Type 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Growth Hormone Deficiency Market: Treatment Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Therapeutic Treatment
  • 5.2.2. Recombinant Human Growth Hormone
  • 5.2.3. Human Pituitary Gland Extracts
  • 5.2.4. Surgery

Chapter 6. Global Growth Hormone Deficiency Market Size & Forecasts by Disease Indication 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Growth Hormone Deficiency Market: Disease Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Pediatric Growth Hormone Deficiency
  • 6.2.2. Idiopathic Short Stature
  • 6.2.3. Small for Gestational Age
  • 6.2.4. Turner Syndrome
  • 6.2.5. Adult Growth Hormone Deficiency
  • 6.2.6. Others (Prader-Willi Syndrome, etc.)

Chapter 7. Global Growth Hormone Deficiency Market Size & Forecasts by Route of Administration 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Growth Hormone Deficiency Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Subcutaneous
  • 7.2.2. Intramuscular
  • 7.2.3. Intravenous

Chapter 8. Global Growth Hormone Deficiency Market Size & Forecasts by Distribution Channel 2022-2032

• 8.1. Segment Dashboard
• 8.2. Global Growth Hormone Deficiency Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 8.2.1. Hospital Pharmacies
  • 8.2.2. Retail Pharmacies
  • 8.2.3. Online Pharmacies

Chapter 9. Global Growth Hormone Deficiency Market Size & Forecasts by Region 2022-2032

• 9.1. North America Growth Hormone Deficiency Market
  • 9.1.1. U.S. Growth Hormone Deficiency Market
    • 9.1.1.1. Treatment Type breakdown size & forecasts, 2022-2032
    • 9.1.1.2. Disease Indication breakdown size & forecasts, 2022-2032
    • 9.1.1.3. Route of Administration breakdown size & forecasts, 2022-2032
    • 9.1.1.4. Distribution Channel breakdown size & forecasts, 2022-2032
  • 9.1.2. Canada Growth Hormone Deficiency Market
• 9.2. Europe Growth Hormone Deficiency Market
  • 9.2.1. U.K. Growth Hormone Deficiency Market
  • 9.2.2. Germany Growth Hormone Deficiency Market
  • 9.2.3. France Growth Hormone Deficiency Market
  • 9.2.4. Spain Growth Hormone Deficiency Market
  • 9.2.5. Italy Growth Hormone Deficiency Market
  • 9.2.6. Rest of Europe Growth Hormone Deficiency Market
• 9.3. Asia-Pacific Growth Hormone Deficiency Market
  • 9.3.1. China Growth Hormone Deficiency Market
  • 9.3.2. India Growth Hormone Deficiency Market
  • 9.3.3. Japan Growth Hormone Deficiency Market
  • 9.3.4. Australia Growth Hormone Deficiency Market
  • 9.3.5. South Korea Growth Hormone Deficiency Market
  • 9.3.6. Rest of Asia Pacific Growth Hormone Deficiency Market
• 9.4. Latin America Growth Hormone Deficiency Market
  • 9.4.1. Brazil Growth Hormone Deficiency Market
  • 9.4.2. Mexico Growth Hormone Deficiency Market
  • 9.4.3. Rest of Latin America Growth Hormone Deficiency Market
• 9.5. Middle East & Africa Growth Hormone Deficiency Market
  • 9.5.1. Saudi Arabia Growth Hormone Deficiency Market
  • 9.5.2. South Africa Growth Hormone Deficiency Market
  • 9.5.3. Rest of Middle East & Africa Growth Hormone Deficiency Market

Chapter 10. Competitive Intelligence

• 10.1. Key Company SWOT Analysis
• 10.2. Top Market Strategies
• 10.3. Company Profiles
  • 10.3.1. Novo Nordisk A/S
    • 10.3.1.1. Key Information
    • 10.3.1.2. Overview
    • 10.3.1.3. Financial (Subject to Data Availability)
    • 10.3.1.4. Product Summary
    • 10.3.1.5. Market Strategies
  • 10.3.2. Pfizer Inc.
  • 10.3.3. Merck KGaA
  • 10.3.4. Eli Lilly and Company
  • 10.3.5. Novartis AG
  • 10.3.6. F. Hoffmann-La Roche AG
  • 10.3.7. Ipsen Pharma
  • 10.3.8. Ferring Pharmaceuticals
  • 10.3.9. Anhui Anke Biotechnology (Group) Co., Ltd.
  • 10.3.10. Zhongshan Sinobioway Hygene Biomedicine Co., Ltd.

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes